The mean IGF-I levels of individuals in Cohort 3 (weekly equivalent of 55. 5% of daily r-hGH) were within 1 . 5 SDS for a imply of 139h and within 2 SDS for a imply of 146h (87% in the week). included 2 stages: Stage A assessed the effectiveness and PK/PD information of the 4 dosing regimens of MOD-4023. Stage W was an extension period of once-weekly MOD-4023 operations (61. 7% molar hGH content) to collect further protection data and confirm the results from Stage A. == Results == Dose-dependent response was observed to get both PK and PD data of weekly MOD-4023 treatment. Insulin-like growth aspect I (IGF-I) SDS levels were managed within regular range. The 18. 5% cohort was discontinued due to low efficacy. MOD-4023 was well tolerated and exhibited favorable protection profile in all dose cohorts. The reported adverse occasions were consistent with known GH-related side effects. == Conclusions == Once-weekly MOD-4023 administration in GHD adults was identified to be clinically effective while maintaining a favorable protection profile and could obviate the need for daily injections. Weekly GH injections might improve compliance and overall outcome. The promising results achieved in Jujuboside B this Phase 2 study led to a pivotal Phase several trial, which is currently regular. == Launch == The primary goal of growth hormone (GH) replacement in adults is to correct the abnormalities associated with GH deficiency (GHD). Current guidelines for the use of r-hGH in adults recommend individualized dosing based on serum IGF-I levels and PRKM8IP the absence of adverse occasions (AEs) (1, 2, 3). The exhibited benefits of Jujuboside B GH therapy consist of improvement in body structure, surrogate markers of aerobic Jujuboside B risk factors, exercise capacity, skeletal honesty and quality of life (1, 2, 3, 4, 5, 6). GH treatment currently requires administration using daily subcutaneous injections (1, 3). However , adherence to this regimen has been shown to be suboptimal (7, 8). This is important since GH alternative is required not only for growth during child years but also for metabolic health during adulthood (9). Long-term continuous GH direct exposure in adult patients with GHD created comparable responses in terms of bone tissue metabolism, body composition, insulin sensitivity and lipid metabolism as with daily GH injections (10, 11). A GH treatment regimen that requires fewer frequent injections may improve adherence and, potentially, overall outcomes (12). A variety Jujuboside B of strategies have been utilized to prolong the duration of GH action, and several are currently undergoing clinical trials (13, 14). Carboxy-terminal peptide (CTP) technology (OPKO Biologics) has enabled the production of a long-acting hGH (MOD-4023), which may obviate the need for the numerous injections now required for the treatment of GHD in children and adults. CTP technology is based on a natural peptide, derived from the C-terminus of human chorionic gonadotropin (hCG (15)), which prolonged the half-life and increased the bioavailability of proteins such as FSH (16) and erythropoietin (17). hGH-CTP (MOD-4023) was shown in pet models to have a significantly longer half-life than r-hGH (18) and a favorable safety profile in Jujuboside B a Phase 1 clinical study conducted in healthy volunteers (19). Based on these findings, MOD-4023 has the potential to be injected once per week, as opposed to the current need for daily hGH injections. The present investigation (ClinicalTrials. gov identifier Nbib1225666) was designed as a dose-finding study to assess the safety, tolerability and PK/PD parameters of an individualized dose of MOD-4023 in adult GHD patients switched from ongoing daily GH injections to less frequent dosing. == Subjects and methods == == Subjects == Eligible patients for this study were males between 23 and 60 and females between 23 and 50 years of age, defined as GHD according to the 2007 Consensus Guidelines (2), who had taken GH replacement therapy for more than 6 months. Because the normal range for IGF-I varies with age, the entry criterion for patients enrollment was set at a standard deviation score (SDS) target range of 1 . 5 IGF-I for gender and chronological age, to minimize data variability. The eligibility criterion for body mass index (BMI) was between 19 and 35 kg/m2. All patients were confirmed as negative for anti-GH antibodies at screening. Patients were excluded from the study if they had evidence of growth of pituitary adenoma or other intracranial tumors, history of malignancy, intracranial hypertension, significant heart failure, impaired liver or kidney function, active acromegaly, glucocorticoid therapy or syndromes such as PraderWilli or Cushings. All study subjects provided written informed consent prior to study initiation. == Study design == This was a multicenter, multi-dose, open-label dose-finding Phase 2 study to evaluate the safety, tolerability and PK/PD profile of MOD-4023 administered subcutaneously to GHD adults on daily hGH therapy. The protocol was reviewed and approved by the Ethics committees of all study sites, and written informed consent was obtained from all patients participating in the study. The study began with a screening period to assess patients eligibility for the study. After the screening period (up to 21 days), the study was composed of two stages (Fig. 1). Stage A was divided into three periods: (I) 3- to 9-week period during which each patients daily r-hGH dose was optimized to.